Research programme: factor IX gene therapy - Cassava Sciencesd
Latest Information Update: 01 Apr 2019
Price :
$50 *
At a glance
- Originator Stanford University School of Medicine
- Developer Cassava Sciences
- Class Gene therapies
- Mechanism of Action Factor IX stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 27 Mar 2019 Pain Therapeutics is now called Cassava Sciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-B in USA (Parenteral, Injection)
- 07 Sep 2010 This programme is still in active development